WebNicolas Dubois, C Omar F Kamlin, Karl Heinz Weiss, on behalf of the CHELATE trial investigators* Summary. Background Wilson disease is an inherited disorder of copper transport. Whereas penicillamine is used therapeutically . to re-establish copper balance, trientine is indicated for patients with penicillamine intolerance. We aimed to compare WebMar 31, 2024 · A noninterventional real-world evidence study in patients with Wilson disease aims to assess the clinical utility of copper parameter measurements using a new nonceruloplasmin-bound copper assay based on copper protein speciation (NCC-Sp). The study is estimated to start in April 2024, and the estimated completion date is December …
Tetrathiomolybdate, a copper chelator for the treatment of Wilson ...
WebStable patients who are already considered to be stable on their standard-of-care penicillamine chelation therapy for at least 1 year will enroll in the study and enter a 12-week Penicillamine Baseline Period comprising of 1 month (4 weeks) run-in period followed by a 2 month (8 weeks) evaluation period. ... Patient's Wilson's disease is ... WebResearch summary. CHELATE STUDY: Trientine tetrahydrocloride (TETA 4 HCl) for the treatment of Wilson’s disease. In this trial a new drug named TETA 4HCl (trientine tetrahydrochloride or TETA 4HCl) will be studied, which is still being clinically investigated, i.e., it has not yet been approved for marketing. A total of approximately 55 ... party patty
Monitoring and treatment of Wilson disease: progress and …
WebFeb 28, 2024 · The CHELATE trial used the NCC as a biomarker for an endpoint in a clinical trial, as we did with the GD trial, and this is so important when you have such a heterogenous disease phenotype. Identifying a biomarker that can predict disease progression is of the utmost priority in all diseases. WebMay 3, 2024 · Wilson's disease is a rare genetic copper transport disorder that mainly affects the liver, brain, and eyes, and can be fatal if left untreated. ... phase III CHELATE trial. The study demonstrated ... WebMay 2, 2024 · Orphalan recently completed a global phase III trial, CHELATE, which met its primary efficacy endpoint by demonstrating that Cuvrior™ was non-inferior to penicillamine as measured by non-ceruloplasmin copper (NCC). ... Wilson Disease Association, added: “Wilson’s disease is a devastating disorder affecting patients worldwide and for which ... tindersticks buried bones